Frequently Asked Questions
The market is segmented based on North America Point-Of-Care Diagnostics Market, By Product (Glucose Monitoring Products, Cardiometabolic, Infectious Disease, Coagulation, Pregnancy, and Fertility, Tumour or Cancer Marker, Urinalysis, Cholesterol, Haematology, Drugs-of-Abuse, Fecal Occult, and Others), Platform (Lateral Flow Assays (Immunochromatography Tests), Dipsticks, Microfluidics, Molecular Diagnostics, and Immunoassays), Prescription (Prescription-Based Testing and OTC Testing), End User (Clinical Laboratories, Outpatient Healthcare and Ambulatory Care Settings, Hospitals or Critical Care Centres, Home Care, Research Laboratories and Others) – Industry Trends and Forecast to 2031.
.
The North America Point Of Care Diagnostics Market size was valued at USD 18.62 USD Billion in 2023.
The North America Point Of Care Diagnostics Market is projected to grow at a CAGR of 6.2% during the forecast period of 2024 to 2031.
The major players operating in the market include , Abbott. , Danaher B.D. , QIAGEN , F. Hoffmann,La Roche Ltd , Johnson & Johnson Private Limited , bioMérieux SA , Trividia Health , , Siemens Healthcare GmbH , Quidel Corporation , Spectral Medical , , Abaxis , Nova Biomedical , Trinity Biotech , Alfa Scientific Designs , , Bio,Rad Laboratories ,.
The market report covers data from the U.S., Canada and Mexico in North America.
